Literature DB >> 22180419

IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection.

Vito Di Marco1, Fabrizio Bronte, Vincenza Calvaruso, Marcello Capra, Zelia Borsellino, Aurelio Maggio, Maria Concetta Renda, Lorella Pitrolo, Maria Carmela Lo Pinto, Michele Rizzo, Flavia Fiorenza, Calogera Gerardi, Stefania Grimaudo, Antonietta Di Cristina, Massimo Levrero, Antonio Craxì.   

Abstract

BACKGROUND: Polymorphisms in the interleukin-28B are important determinants in the spontaneous and drug-induced control of hepatitis C virus infection. DESIGN AND METHODS: We assessed the association of rs8099917 and rs12979860 polymorphisms with spontaneous viral clearance, severity of liver fibrosis, and response to interferon-monotherapy in 245 thalassemia major patients with hepatitis C virus infection.
RESULTS: Ninety-eight patients (40%) had a spontaneous viral clearance while 147 patients (60%) developed a chronic infection. Spontaneous viral clearance was more frequent among patients with the T/T genotype of rs8099917 polymorphism (OR 2.130; P = 0.008) or C/C genotype of rs12979860 polymorphism (OR 2.425; P = 0.001). During observation, 131 patients with chronic infection underwent a liver biopsy; age (OR 1.058; P = 0.01) G/T or G/G genotypes of rs8099917 polymorphism (OR 3.962; P = 0.001), and C/T or T/T genotypes of rs12979860 polymorphism (OR 3.494; P = 0.005) were associated with severe liver fibrosis, independent of liver iron concentration. Finally, T/T genotype of rs8099917 polymorphism (OR 3.014; P = 0.03) or C/C genotype of rs12979860 polymorphism (OR 3.285; P = 0.01), age (OR 0.902; P = 0.001), female gender (OR 3.418; P = 0.01) and 2 or 3 virus C genotypes (OR 4.700; P=0.007) were independently associated with sustained virological response in 114 patients treated with alpha-interferon. Conclusions Polymorphisms in the interleukin-28B are associated with the control of hepatitis C virus infection in thalassemia major patients, and understanding allelic patterns has an important role in determining prognosis and therapeutic management.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22180419      PMCID: PMC3342968          DOI: 10.3324/haematol.2011.050351

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  30 in total

1.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

Authors: 
Journal:  J Hepatol       Date:  2011-03-01       Impact factor: 25.083

2.  Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection.

Authors:  Francesco Marabita; Alessio Aghemo; Stella De Nicola; Maria G Rumi; Cristina Cheroni; Rossana Scavelli; Marco Crimi; Roberta Soffredini; Sergio Abrignani; Raffaele De Francesco; Massimo Colombo
Journal:  Hepatology       Date:  2011-08-19       Impact factor: 17.425

3.  IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.

Authors:  Amir Moghaddam; Espen Melum; Nils Reinton; Helmer Ring-Larsen; Hans Verbaan; Kristian Bjøro; Olav Dalgard
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

4.  Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients.

Authors:  Christoph Sarrazin; Simone Susser; Alexandra Doehring; Christian Markus Lange; Tobias Müller; Christina Schlecker; Eva Herrmann; Jörn Lötsch; Thomas Berg
Journal:  J Hepatol       Date:  2010-09-22       Impact factor: 25.083

5.  IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC.

Authors:  Carlo Fabris; Edmondo Falleti; Annarosa Cussigh; Davide Bitetto; Elisabetta Fontanini; Sara Bignulin; Sara Cmet; Ezio Fornasiere; Elisa Fumolo; Stefano Fangazio; Andrea Cerutti; Rosalba Minisini; Mario Pirisi; Pierluigi Toniutto
Journal:  J Hepatol       Date:  2010-09-19       Impact factor: 25.083

6.  Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel.

Authors:  Vito Di Marco; Marcello Capra; Emanuele Angelucci; Caterina Borgna-Pignatti; Paul Telfer; Paul Harmatz; Antonis Kattamis; Luciano Prossamariti; Aldo Filosa; Deborah Rund; Maria Rita Gamberini; Paolo Cianciulli; Marianne De Montalembert; Francesco Gagliardotto; Graham Foster; Jean Didier Grangè; Filippo Cassarà; Angela Iacono; Maria Domenica Cappellini; Gary M Brittenham; Daniele Prati; Antonello Pietrangelo; Antonio Craxì; Aurelio Maggio
Journal:  Blood       Date:  2010-06-15       Impact factor: 22.113

Review 7.  Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment.

Authors:  Manuel Romero-Gomez; Mohamed Eslam; Agustín Ruiz; Marta Maraver
Journal:  Liver Int       Date:  2011-01-30       Impact factor: 5.828

8.  A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice.

Authors:  Hans L Tillmann; Alex J Thompson; Keyur Patel; Manfred Wiese; Hannelore Tenckhoff; Hans D Nischalke; Yuliya Lokhnygina; Ulrike Kullig; Uwe Göbel; Emanuela Capka; Johannes Wiegand; Ingolf Schiefke; Wolfgang Güthoff; Kurt Grüngreiff; Ingrid König; Ulrich Spengler; Jeanette McCarthy; Kevin V Shianna; David B Goldstein; John G McHutchison; Jörg Timm; Jacob Nattermann
Journal:  Gastroenterology       Date:  2010-07-14       Impact factor: 22.682

9.  A multicenter prospective study on the risk of acquiring liver disease in anti-hepatitis C virus negative patients affected from homozygous beta-thalassemia.

Authors:  D Prati; A Zanella; E Farma; C De Mattei; P Bosoni; M Zappa; A Picone; F Mozzi; P Rebulla; M D Cappellini; J P Allain; G Sirchia
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

10.  Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype.

Authors:  Edmondo Falleti; Davide Bitetto; Carlo Fabris; Annarosa Cussigh; Ezio Fornasiere; Sara Cmet; Elisa Fumolo; Sara Bignulin; Elisabetta Fontanini; Andrea Cerutti; Rosalba Minisini; Mario Pirisi; Pierluigi Toniutto
Journal:  J Clin Immunol       Date:  2011-06-07       Impact factor: 8.542

View more
  17 in total

1.  Interleukin 28A.rs12980602 and interleukin 28B.rs8103142 genotypes could be protective against HCV infection among Egyptians.

Authors:  Zainab A Zakaria; Susanne Knapp; Mohamed Hashem; Hassan Zaghla; Mark Thursz; Imam Waked; Sayed Abdelwahab
Journal:  Immunol Res       Date:  2019-02       Impact factor: 2.829

2.  Interferon-λ rs12979860 genotype association with liver fibrosis in chronic hepatitis C (CHC) patients in the Pakistani population.

Authors:  Bisma Rauff; Ali Amar; Shafiq Ahmad Chudhary; Saqib Mahmood; Ghias Un Nabi Tayyab; Rumeza Hanif
Journal:  Arch Virol       Date:  2021-02-02       Impact factor: 2.574

Review 3.  The role of IFNL4 in liver inflammation and progression of fibrosis.

Authors:  Michelle Møhlenberg; Thomas R O'Brien; Rune Hartmann
Journal:  Genes Immun       Date:  2022-05-18       Impact factor: 2.676

4.  Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis.

Authors:  Mazen Noureddin; Elizabeth C Wright; Harvey J Alter; Shauna Clark; Emmanuel Thomas; Richard Chen; Xiongce Zhao; Cathy Conry-Cantilena; David E Kleiner; T Jake Liang; Marc G Ghany
Journal:  Hepatology       Date:  2013-09-30       Impact factor: 17.425

5.  Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin.

Authors:  Tatsuo Miyamura; Tatsuo Kanda; Shingo Nakamoto; Shuang Wu; Xia Jiang; Makoto Arai; Keiichi Fujiwara; Fumio Imazeki; Osamu Yokosuka
Journal:  Viruses       Date:  2012-08-14       Impact factor: 5.048

6.  Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.

Authors:  María A Jiménez-Sousa; Amanda Fernández-Rodríguez; María Guzmán-Fulgencio; Mónica García-Álvarez; Salvador Resino
Journal:  BMC Med       Date:  2013-01-08       Impact factor: 8.775

7.  Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease.

Authors:  José A Agúndez; Elena García-Martin; María L Maestro; Francisca Cuenca; Carmen Martínez; Luis Ortega; Miguel Carballo; Marta Vidaurreta; Marta Agreda; Gabriela Díaz-Zelaya; Avelina Suárez; Manuel Díaz-Rubio; José M Ladero
Journal:  PLoS One       Date:  2012-05-29       Impact factor: 3.240

8.  Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy.

Authors:  Saleh Sandoughdaran; Seyed Moayed Alavian; Heidar Sharafi; Bita Behnava; Shima Salimi; Leila Mehrnoush; Pegah Karimi Elizee; Maryam Keshvari
Journal:  Hepat Mon       Date:  2015-01-13       Impact factor: 0.660

9.  Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease.

Authors:  Mohammed Eslam; Ahmed M Hashem; Reynold Leung; Manuel Romero-Gomez; Thomas Berg; Gregory J Dore; Henry L K Chan; William L Irving; David Sheridan; Maria L Abate; Leon A Adams; Alessandra Mangia; Martin Weltman; Elisabetta Bugianesi; Ulrich Spengler; Olfat Shaker; Janett Fischer; Lindsay Mollison; Wendy Cheng; Elizabeth Powell; Jacob Nattermann; Stephen Riordan; Duncan McLeod; Nicola J Armstrong; Mark W Douglas; Christopher Liddle; David R Booth; Jacob George; Golo Ahlenstiel
Journal:  Nat Commun       Date:  2015-03-05       Impact factor: 14.919

10.  Genetic variation in the interleukin-28B gene is associated with spontaneous clearance and progression of hepatitis C virus in Moroccan patients.

Authors:  Sayeh Ezzikouri; Rhimou Alaoui; Khadija Rebbani; Ikram Brahim; Fatima-Zohra Fakhir; Salwa Nadir; Helmut Diepolder; Salim I Khakoo; Mark Thursz; Soumaya Benjelloun
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.